-
Switching between complement inhibitors in patients with PNH: A real-world analysis of strategy, efficacy, and safety.2025 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Morag Griffin, Bruno Fattizzo, Jong Wook Lee, Richard J. Kelly, Roochi Trikha, Yasutaka Ueda, +10 more
0citations -
Elevation of fetal hemoglobin is a biomarker for response to decitabine in AML: Results of the AML21 randomized phase III trial of the EORTC leukemia group, gimema and german MDS study group
Julia Stomper, Michal Kiciński, Tobias Ma, Sylvain Chantepie, Richard Noppeney, Mario Luppi, +16 more
0citations -
Multicenter Phase II trial of enasidenib as maintenance treatment following allogeneic stem cell transplantation in IDH2-mutated myeloid neoplasms – the IDH2-post-allo-trial (NCT04522895)
Thomas Schroeder, Matthias Stelljes, Edgar Jost, Jan Moritz Middeke, Gesine Bug, Georg‐Nikolaus Franke, +10 more
0citations -
Final results from a prospective, multicenter, non-interventional study (BESREMi-PASS) on the safety of ropeginterferon alfa-2b in 229 patients with polycythemia vera2025 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Veronika Buxhofer‐Ausch, Andreas Reiter, Ciprian Tomuleasa, Albert Woelfler, Lino Lars Teichmann, Luminita Ocroteala, +7 more
0citations -
Long-term outcome and risk factors for relapse after allogeneic hematopoietic stem cell transplantation in myelofibrosis: Results from a large multicenter cohort2025 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Julia-Annabell Georgi, Sebastian Stasik, Michael Krämer, Tobias A.W. Holderried, Jochen J. Frietsch, Stefan Klein, +18 more
0citations -
Risk factors for progressive kidney impairment among patients with polycythemia vera (PV) are recapitulated and treatable in mouse models of PV2025 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Brandi Reeves, Marcelo A. S. Toledo, Fatima Trebak, Małgorzata Kasztan, Vimal Kumar Derebail, Rafał Pawliński, +4 more
0citations -
Real-world clinical characteristics and treatment outcomes in PNH patients prescribed pegcetacoplan across europe, the United States and Canada2025 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Jens Panse, Koo Wilson, Sam Williamson, Susanna Libby, Peter Hillmen, David Dingli
0citations -
Adding eltrombopag to immunosuppressive treatment with cyclosporine as front-line therapy for moderate aplastic anemia improves trilineage hematologic response: One-year analysis of the randomised, placebo-controlled, double-blind Phase III trial eltrombopag for moderate aplastic anemia (EMAA Trial)2025 Blood conference-abstract Biochemistry, Genetics and Molecular Biology Blood disorders and treatments Open access
Britta Hoechsmann, Philippe Schafhausen, Fabian Beier, Michael Heuser, Joerg Westermann, Beatrice Drexler, +10 more
0citations -
Thymoglobuline and grafalon show comparable transplant outcomes in patients with aplastic anemia undergoing allogeneic stem cell transplantation: A multicenter EBMT saawp study of 1603 patients
Fabian Beier, Edgar Jost, Dirk‐Jan Eikema, Joe Tuffnell, Brian Piepenbroek, Malek Benakli, +20 more
0citations -
Outcome of adult B-precursor acute lymphoblastic leukemia (ALL) treated with blinatumomab in addition to chemotherapy independent of MRD: First results from the national GMALL registry
Nicola Gökbuget, Matthias Stelljes, Walter Fiedler, Jens Panse, Andreas Viardot, Lisa Heberling, +14 more
0citations -
Health-related quality of life (HRQoL) in patients with newly diagnosed multiple myeloma (NDMM) eligible for transplantation and treated with isatuximab, lenalidomide, bortezomib, and dexamethasone (Isa-RVd) versus rvd alone: Results from part 1 of the GMMG-HD7 study
Roland Schroers, Lisa Beatrice Leypoldt, Christof Scheid, Evgenii Shumilov, Christoph Lutz
0citations